MIRIKIZUMAB - A NEW OPTION IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES

被引：0

作者：

Olszewski, Jakub ^{[1
]}

Kozon, Katarzyna ^{[1
]}

Sitnik, Magdalena ^{[1
]}

Herjan, Katarzyna ^{[2
]}

Mikolap, Karolina ^{[3
]}

Gastol, Bartlomiej ^{[4
]}

Bara, Maciej ^{[5
]}

Armanski, Piotr ^{[6
]}

Sawczuk, Marcin ^{[7
]}

机构：

[1] Masovian Brodnowski Hosp, PL-03242 Warsaw, Poland

[2] Prof W Orlowski Mem Hosp, PL-00401 Warsaw, Poland

[3] Wolski Hosp Warsaw, PL-01211 Warsaw, Poland

[4] Masovian Specialist Hosp Ostroleka, PL-07410 Ostroleka, Poland

[5] Med Univ Warsaw, Infant Jesus Clin Hosp, PL-02005 Warsaw, Poland

[6] Dist Hosp Sochaczew, PL-96500 Sochaczew, Poland

[7] Med Univ Gdansk, Clin Ctr, PL-80952 Gdansk, Poland

来源：

PROSPECTS IN PHARMACEUTICAL SCIENCES | 2024年 / 22卷 / 03期

关键词：

mirikizumab; IL-23; ulcerative colitis; ULCERATIVE-COLITIS; MAINTENANCE THERAPY; INTERLEUKIN-23; DIAGNOSIS; INDUCTION;

D O I：

10.56782/pps.262

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Mirikizumab is a humanized monoclonal antibody targeting the p19 subunit of interleukin IL-23. Over the past few years, it has been the subject of clinical trials as a potential new treatment for inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Additionally, mirikizumab has been investigated in clinical trials as a potential treatment for plaque psoriasis. The results of clinical trials for mirikizumab in treating ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for treating adult patients with moderately to severely active ulcerative colitis. Despite promising clinical trial results, mirikizumab has not yet been approved for the treatment of Crohn's disease. This review focuses on summarizing the findings from clinical trials of mirikizumab in the treatment of inflammatory bowel diseases. Information is sourced from scientific papers available on PubMed, by searching for "mirikizumab" and "IL-23" and published to March 2024, as well as from published results of clinical trials concerning mirikizumab.

引用

页码：178 / 185

页数：8

共 50 条

[1] Pharmacology and metabolism of infliximab biosimilars - A new treatment option in inflammatory bowel diseases
Wlodarczyk, Marcin
Fichna, Jakub
Sobolewska-Wlodarczyk, Aleksandra
PHARMACOLOGICAL REPORTS, 2016, 68 (04) : 797 - 801
[2] A New Option for the Treatment of Inflammatory Diseases
不详
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (01) : 7 - 7
[3] Pharmacology and metabolism of infliximab biosimilars — A new treatment option in inflammatory bowel diseases
Marcin Włodarczyk
Jakub Fichna
Aleksandra Sobolewska-Włodarczyk
Pharmacological Reports, 2016, 68 : 797 - 801
[4] Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis
Choi, David
Sheridan, Hilary
Bhat, Shubha
ANNALS OF PHARMACOTHERAPY, 2024,
[5] New treatment options for inflammatory bowel diseases
Bram Verstockt
Marc Ferrante
Séverine Vermeire
Gert Van Assche
Journal of Gastroenterology, 2018, 53 : 585 - 590
[6] New treatment options for inflammatory bowel diseases
Verstockt, Bram
Ferrante, Marc
Vermeire, Severine
Van Assche, Gert
JOURNAL OF GASTROENTEROLOGY, 2018, 53 (05) : 585 - 590
[7] New therapies in the treatment of inflammatory bowel diseases
Marth, T
CHIRURGISCHE GASTROENTEROLOGIE, 2002, 18 (04): : 341 - 348
[8] New biologics for treatment of chronic inflammatory bowel diseases
Schreiber, S.
Bachmann, O.
INTERNIST, 2014, 55 (04): : 367 - +
[9] New breakthrough in the treatment of inflammatory bowel diseases (IBD)
Assaf, Peter
Gazaleen-Marie, Elham
Duerr, Joel
NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2006, 14 (04): : A48 - A48
[10] Early Surgery in Inflammatory Bowel Diseases Is a Better Option than Prolonged Conservative Treatment
Kroesen, Anton J.
VISCERAL MEDICINE, 2019, 35 (06) : 355 - 357

← 1 2 3 4 5 →